Testing

Joseph Yao, M.D., gives an overview of this new test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.

Neuro-oncology is a complex field undergoing rapid changes with the advancement and evolution of sophisticated genetic testing. Evidence continues to grow in support of broad molecular and cytogenetic analysis for patients with brain tumors.

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of April 2019.

The diagnosis of mitochondrial disease can be particularly challenging as the presentation can occur at any age, involve virtually any organ system, and be associated with widely varying severities. Due to the considerable overlap in the clinical phenotypes of various mitochondrial disorders, it is often difficult to distinguish these specific inherited disorders without genetic testing.

In April 2019, Mayo Clinic Laboratories announced nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The current diagnostic tools in a pathologist’s arsenal sometimes cannot provide a clear distinction between primary mediastinal large B-cell lymphoma (one of the few lymphomas more common in younger women) and diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma overall.

The standard laboratory test to diagnose multiple myeloma dates back to the Eisenhower administration. Research at Mayo Clinic spearheaded by David Murray, M.D., Ph.D. (PATH ’10), and fueled by his experience as an industrial chemist has led to a new assay to screen and diagnose the disease.

Joshua Bornhorst, Ph.D., gives an overview of the new Copeptin test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of March 2019.

In March 2019, Mayo Clinic Laboratories announced six new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of February 2019.

Breath Diagnostics, Inc. and Mayo Clinic Laboratories have announced a collaboration to develop clinical diagnostic tests that use patient breath samples to identify individual biomarkers that can predict a spectrum of diseases. The two organizations will initially focus on a test that can detect lung cancer.

Jeffrey (Jeff) Meeusen, Ph.D., gives an overview of the new nuclear magnetic resonance (NMR) lipoprotein profile available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.